PreprintReviewVersion 1Preserved in Portico This version is not peer-reviewed
Combining Immunotherapy with Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma-The Rationale and Review of Literature
Version 1
: Received: 25 July 2024 / Approved: 29 July 2024 / Online: 29 July 2024 (07:54:11 CEST)
How to cite:
Elhariri, A.; Elsheikh, M.; Elsabagh, A.; Badr, I.; Ibrahim, M. A.; Bhongade, M.; Albarouki, S.; Hassan, M.; Jalal, P. K. Combining Immunotherapy with Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma-The Rationale and Review of Literature. Preprints2024, 2024072257. https://doi.org/10.20944/preprints202407.2257.v1
Elhariri, A.; Elsheikh, M.; Elsabagh, A.; Badr, I.; Ibrahim, M. A.; Bhongade, M.; Albarouki, S.; Hassan, M.; Jalal, P. K. Combining Immunotherapy with Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma-The Rationale and Review of Literature. Preprints 2024, 2024072257. https://doi.org/10.20944/preprints202407.2257.v1
Elhariri, A.; Elsheikh, M.; Elsabagh, A.; Badr, I.; Ibrahim, M. A.; Bhongade, M.; Albarouki, S.; Hassan, M.; Jalal, P. K. Combining Immunotherapy with Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma-The Rationale and Review of Literature. Preprints2024, 2024072257. https://doi.org/10.20944/preprints202407.2257.v1
APA Style
Elhariri, A., Elsheikh, M., Elsabagh, A., Badr, I., Ibrahim, M. A., Bhongade, M., Albarouki, S., Hassan, M., & Jalal, P. K. (2024). Combining Immunotherapy with Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma-The Rationale and Review of Literature. Preprints. https://doi.org/10.20944/preprints202407.2257.v1
Chicago/Turabian Style
Elhariri, A., Manal Hassan and Prasun K Jalal. 2024 "Combining Immunotherapy with Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma-The Rationale and Review of Literature" Preprints. https://doi.org/10.20944/preprints202407.2257.v1
Abstract
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide and a major global health burden. The treatment of HCC has experienced a paradigm shift in the last few years, following the discovery of immunotherapy. However, despite the profound success of immunotherapy in other cancer types, their response in HCC remains unsatisfactory. Some of the reasons that can explain this poor response include the immunosuppressive microenvironment of HCC, the absence of reliable biomarkers for response, and drug resistance. Previous preclinical and clinical studies have highlighted the role of combination therapy in overcoming some of these hurdles. In this article, we discuss the benefit of combining immune checkpoint inhibitors (ICIs) with stereotactic body radiation therapy (SBRT) in HCC and shed light on promising clinical trials.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
